Table 2.

Cytotoxic activity of oxadiazole/chalcone hybrids, 8a-x, against three leukemia cell lines.

Compound	(IC50 μM) ± SD
	K-562	KG-1a	Jurkat
8a	7.21 ± 0.35	8.85 ± 0.22	8.47 ± 1.03
8b	75.35 ± 4.61	82.24 ± 4.56	78.71 ± 2.13
8c	69.54 ± 5.15	95.22 ± 3.88	75.22 ± 1.25
8d	22.84 ± 1.32	31.34 ± 1.05	28.28 ± 0.62
8e	93.31 ± 5.21	>100	>100
8f	82.27 ± 3.08	91.54 ± 4.15	88.61 ± 1.35
8g	13.05 ± 1.65	55.64 ± 1.34	41.21 ± 0.91
8 h	72.14 ± 3.32	84.64 ± 5.21	78.06 ± 2.10
8i	55.34 ± 4.89	78.95 ± 3.02	62.56 ± 1.37
8j	22.61 ± 2.34	25.22 ± 0.48	31.13 ± 0.46
8k	58.42 ± 3.75	71.07 ± 1.22	62.67 ± 2.71
8 l	35.22 ± 2.05	38.32 ± 2.45	33.28 ± 1.22
8m	23.11 ± 0.28	31.54 ± 0.42	28.36 ± 0.85
8n	10.25 ± 0.94	15.97 ± 0.96	13.15 ± 0.08
8o	58.37 ± 5.45	65.64 ± 2.31	94.09 ± 5.31
8p	16.09 ± 1.08	22.52 ± 1.07	17.24 ± 0.79
8q	40.22 ± 2.82	45.29 ± 2.31	31.94 ± 1.30
8r	>100	93.08 ± 1.14	>100
8s	15.14 ± 0.25	32.12 ± 0.64	25.14 ± 0.45
8 t	73.25 ± 3.72	84.57 ± 1.28	76.36 ± 1.31
8u	84.22 ± 4.36	95.69 ± 2.48	>100
8v	1.95 ± 0.18	3.45 ± 0.25	2.36 ± 0.47
8w	90.34 ± 2.91	>100	>100
8x	62.15 ± 3.07	71.48 ± 1.18	69.17 ± 0.15
Cisplatin	3.21 ± 0.45	12.15 ± 3.41	15.12 ± 1.35